Cemavafusp Biosimilar - Research Grade

Out of stock

Only %1 left

SKU

ICH5431-10mg

Add to Compare

Be the first to review this product

Cemavafusp Biosimilar - Research Grade

Endotoxin

≤ 1.0 EU/mg as determined by the LAL method

Purity

>90% by SDS-PAGE

Species Reactivity

Human

Target

PD-L1

Concentration

>1mg/ml

Isotype

scFv - heavy - kappa

Host

CHO Cells

Antibodies Against The Same Target

Sequence

https://www.imgt.org/mAb-DB/

Buffer

ICH3002

Uniprot

Q9NZQ7

Shipping Conditions

Blue ice

Background

This research-grade product is supplied as an unconjugated, non-therapeutic analog related to Cemavafusp, offered for laboratory use only and not for clinical or diagnostic application. It is built around binding to human PD-L1 (CD274). Note that the originator Cemavafusp is not a conventional monoclonal antibody or a plain checkpoint-blocking biosimilar: per its International Nonproprietary Name it is an engineered fusion protein that couples an anti-PD-L1 single-chain variable fragment to a Shiga-like toxin subunit and to a viral (CMV pp65) MHC class I epitope, giving it a targeted-delivery / antigen-seeding character rather than a simple receptor-blockade mechanism. For that reason this analog is best positioned as a PD-L1-directed binding reagent and functional research tool rather than as a checkpoint inhibitor. Like other ichorbio research reagents it is intended for in-vitro and functional characterisation work, and can be produced at research (low endotoxin, typically under 1 EU/mg) and ultra-low endotoxin grades for demanding assays. Investigators studying PD-L1 biology, tumour immunology, and targeted-fusion or immunotoxin approaches may find it useful as a binding and assay-development tool. This description is provided as guidance for ichorbio to review before publication; see the flag regarding the product's nature. PD-L1 (Programmed death-ligand 1; gene CD274, also PDCD1LG1; UniProt Q9NZQ7) is a type I transmembrane glycoprotein of the B7 immunoglobulin superfamily. Its principal receptor is PD-1 (PDCD1) on activated T cells; engagement delivers an inhibitory signal that dampens T-cell receptor signalling, promotes T-cell exhaustion, and contributes to peripheral tolerance. PD-L1 also binds CD80 (B7-1). It is expressed on antigen-presenting cells and many other tissues, and is frequently upregulated on tumour cells and within the tumour microenvironment in response to interferon-gamma, allowing tumours to evade immune attack. Because of this role, PD-L1 is a central node in cancer immunotherapy and a widely studied target for both blocking antibodies and, as in the Cemavafusp construct, as a tumour-associated address for targeted delivery of effector or antigen-seeding payloads. It is one of the most heavily investigated immune-checkpoint molecules in oncology research.

Other Names

CD274

Purification Method

This monoclonal antibody was purified using Protein A

Formulation

Sterile, preservative-free, solution in PBS. BSA and Azide free.

Storage

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications

Functional Assays

Application Notes

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.